Item 5.02  Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 7, 2021, the Board of Directors (the "Board") of Zosano Pharma
Corporation (the "Company") appointed Elaine Yang to serve as a member of the
Board, effective immediately. Ms. Yang was appointed as a Class III director, to
serve for an initial term expiring at the Company's 2023 annual meeting of
stockholders and until her successor is duly elected and qualified or until her
earlier death, resignation or removal. Ms. Yang was also appointed to serve as a
member of the Audit Committee of the Board.
Pursuant to the Company's non-employee director compensation program, Ms. Yang
will receive annual cash compensation of $45,000 for her service as a member of
the Board and annual cash compensation of $7,500 for her service as a member of
the Audit Committee of the Board. Also pursuant to the Company's non-employee
director compensation program, Ms. Yang was granted an option to purchase 90,000
shares of its common stock at an exercise price of $0.558 per share, which was
the closing price of the Company's common stock on the Nasdaq Capital Market on
the date of grant.
Ms. Yang and the Company will also enter into the Company's standard form of
indemnification agreement.
On December 10, 2021, Kleanthis Xanthopoulos delivered notice of his intention
to resign from the Board effective as of December 31, 2021. Dr. Xanthopoulos'
resignation from the Board is not a result of a disagreement with the Company on
any matter relating to the Company's operations, policies or practices.

© Edgar Online, source Glimpses